8 Einträge gefunden

1. Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study

   1. Ludwig, Heinz
   2. Bokemeyer, Carsten
   3. Aapro, Matti
   4. Boccadoro, Mario
   5. Gascón, Pere
   6. Denhaerynck, Kris
   7. Krendyukov, Andriy

   2019 - Forschungsinformationssystem des UKE
2. Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated "same-day" ( 72 h): findings from the MONITOR-GCSF study

   1. Ludwig, Heinz
   2. Gascón, Pere
   3. Bokemeyer, Carsten
   4. Aapro, Matti
   5. Boccadoro, Mario
   6. Denhaerynck, Kris
   7. Krendyukov, Andriy

   2019 - Forschungsinformationssystem des UKE
3. Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study

   1. Bokemeyer, Carsten
   2. Gascón, Pere
   3. Aapro, Matti
   4. Ludwig, Heinz
   5. Boccadoro, Mario
   6. Denhaerynck, Kris
   7. Gorray, Michael

   2017 - Forschungsinformationssystem des UKE
4. Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)

   1. Gascón, Pere
   2. Aapro, Matti
   3. Ludwig, Heinz
   4. Bokemeyer, Carsten
   5. Boccadoro, Mario
   6. Turner, Matthew
   7. Denhaerynck, Kris

   2016 - Forschungsinformationssystem des UKE
5. Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in elderly versus non-elderly cancer patients: Patterns, outcomes, and determinants (MONITOR-GCSF study)

   1. Aapro, Matti
   2. Bokemeyer, Carsten
   3. Ludwig, Heinz
   4. Gascón, Pere
   5. Boccadoro, Mario
   6. Denhaerynck, Kris
   7. Gorray, Michael

   2016 - Forschungsinformationssystem des UKE
6. Erratum to: Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)

   1. Gascón, Pere
   2. Aapro, Matti
   3. Ludwig, Heinz
   4. Bokemeyer, Carsten
   5. Boccadoro, Mario
   6. Turner, Matthew
   7. Denhaerynck, Kris

   2015 - Forschungsinformationssystem des UKE
7. Modeling of treatment response to erythropoiesis-stimulating agents in older (age≥70years) and younger (age<70years) patients with cancer and anemia: findings from the Anemia Cancer Treatment study

   1. Abraham, Ivo
   2. MacDonald, Karen
   3. Tharmarajah, Soba
   4. Bokemeyer, Carsten
   5. Ludwig, Heinz
   6. Soubeyran, Pierre
   7. Battistel, Vittorio

   2013 - Forschungsinformationssystem des UKE
8. Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥ 10 g/dL: an exploratory analysis of a phase 3 trial.

   1. Canon, Jean-Luc
   2. Vansteenkiste, Johan
   3. Hedenus, Michael
   4. Gascon, Pere
   5. Bokemeyer, Carsten
   6. Ludwig, Heinz
   7. Vermorken, Jan

   2012 - Forschungsinformationssystem des UKE